Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced the closing of an underwritten public offering of 26,666,666 shares of common stock and warrants to purchase up to 13,333,333 shares of common stock, along with an additional 3,999,999 shares of common stock and 1,999,999 warrants pursuant to the full exercise of the underwriters’ option.

Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced the pricing of an underwritten public offering of (i) 26,666,666 shares of common stock and warrants to purchase up to 13,333,333 shares of common stock.

KRAS is a commonly mutated gene across solid tumors, thus makes it a potential target for anti-tumor drugs. Recently, some developing drugs showed potential in treating the KRAS G12C mutant.

KRAS is the first human oncogene discovered in 1983; however, no any approved KRAS target therapy till now.

Breast cancer is the most common cancer in women. Hormone therapy is the major treatment option for patients with estrogen receptor-positive (ER+) and Her2-negative (Her2-) breast cancer.

N/A

Acepodia, a biotechnology company developing novel off-the-shelf cell therapies against solid tumor and hematologic cancers, will present preclinical data supporting the potential of its lead candidate ACE1702, an off-the-shelf oNK cell therapy, at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting being held virtually from November 9-14, 2020.

Arthrosi Therapeutics, a clinical stage biopharmaceutical company focused on developing a best in class treatment for gout, has completed a Phase 2a clinical trial for company’s lead asset, AR882.

Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products today announced the presentation of data from the Company’s ongoing Phase 1/2 study evaluating ADXS-503 as a monotherapy and in combination with KEYTRUDA^® (pembrolizumab), Merck’s anti-PD-1 therapy in non-small cell lung cancer (NSCLC) at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting.

[Taipei, Taiwan] –  For the Phase III clinical trial of its breast cancer drug EG12014 (Trastuzumab biosimilar, also called EGI014), EirGenix, Inc. (6589.TT) has completed neoadjuvant treatment and surgery of its last patient.